Penn Capital Management Co. Inc. decreased its holdings in shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) by 11.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 267,290 shares of the company’s stock after selling 35,694 shares during the period. Penn Capital Management Co. Inc. owned 1.00% of Oxford Immunotec Global worth $4,605,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in OXFD. Martingale Asset Management L P bought a new position in Oxford Immunotec Global during the 4th quarter valued at approximately $1,499,000. Bellevue Group AG raised its position in Oxford Immunotec Global by 38.2% during the 4th quarter. Bellevue Group AG now owns 306,606 shares of the company’s stock valued at $3,918,000 after purchasing an additional 84,769 shares during the last quarter. Renaissance Technologies LLC raised its position in Oxford Immunotec Global by 390.5% during the 3rd quarter. Renaissance Technologies LLC now owns 103,300 shares of the company’s stock valued at $1,677,000 after purchasing an additional 82,242 shares during the last quarter. Oppenheimer & Co. Inc. bought a new position in Oxford Immunotec Global during the 4th quarter valued at approximately $900,000. Finally, Millennium Management LLC raised its position in Oxford Immunotec Global by 117.2% during the 4th quarter. Millennium Management LLC now owns 117,914 shares of the company’s stock valued at $1,507,000 after purchasing an additional 63,617 shares during the last quarter. 88.87% of the stock is owned by institutional investors and hedge funds.
OXFD stock opened at $15.50 on Thursday. Oxford Immunotec Global PLC has a fifty-two week low of $11.66 and a fifty-two week high of $19.19. The company has a current ratio of 12.60, a quick ratio of 12.03 and a debt-to-equity ratio of 0.04. The company has a market cap of $425.97 million, a price-to-earnings ratio of 30.39 and a beta of 0.32.
Oxford Immunotec Global (NASDAQ:OXFD) last posted its earnings results on Thursday, May 9th. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.14. Oxford Immunotec Global had a return on equity of 13.56% and a net margin of 172.27%. The firm had revenue of $14.79 million for the quarter, compared to the consensus estimate of $13.74 million. During the same quarter in the prior year, the business earned ($0.40) EPS. The business’s revenue for the quarter was up 26.6% on a year-over-year basis. On average, analysts expect that Oxford Immunotec Global PLC will post -0.3 EPS for the current year.
A number of research firms have weighed in on OXFD. Zacks Investment Research downgraded Oxford Immunotec Global from a “buy” rating to a “hold” rating in a report on Thursday, May 2nd. BidaskClub upgraded Oxford Immunotec Global from a “sell” rating to a “hold” rating in a report on Tuesday, May 7th.
In other Oxford Immunotec Global news, CEO Peter Wrighton-Smith sold 10,600 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $16.68, for a total transaction of $176,808.00. Following the transaction, the chief executive officer now owns 445,138 shares in the company, valued at approximately $7,424,901.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Elizabeth M. Keiley sold 4,100 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $17.00, for a total value of $69,700.00. Following the completion of the sale, the senior vice president now owns 26,928 shares in the company, valued at approximately $457,776. The disclosure for this sale can be found here. Insiders have sold a total of 27,700 shares of company stock worth $464,558 in the last quarter. Company insiders own 6.61% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This article was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2019/05/16/oxford-immunotec-global-plc-oxfd-holdings-reduced-by-penn-capital-management-co-inc.html.
Oxford Immunotec Global Profile
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.
Featured Story: What are Bollinger Bands?
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.